Shares of Iovance Biotherapeutics, Inc. (IOVA) are soaring 5.65% in pre-market trading on Monday, following a mixed report from Goldman Sachs. The investment bank raised its price target on IOVA to $1.50 from $1, but surprisingly maintained its Sell rating on the stock.

The conflicting signals from Goldman Sachs have created an interesting dynamic in the market. On one hand, the increased price target suggests some improvement in the bank's outlook for Iovance. This could be based on factors such as potential advancements in the company's biotechnology pipeline or improved financial metrics. On the other hand, the maintained Sell rating indicates that Goldman Sachs still has significant reservations about the company's overall prospects.

Investors appear to be focusing on the positive aspect of the report - the raised price target - which could explain the pre-market surge. However, it's worth noting that even with the increase, the new price target of $1.50 is still relatively low, especially considering the stock's current trading price. As the market opens, it will be interesting to see if this early momentum continues or if traders will reassess their positions in light of the maintained Sell rating.